Twenty-five years after its introduction, ceftazidime remains the most active cephalosporin against Pseudomonas aeruginosa. Nevertheless, resistance arises by upregulation of AmpC -lactamase, by efflux or, less often, via acquisition of additional -lactamases. Mutational resistance is especially prevalent among cystic fibrosis (CF) isolates. We examined the activity of a novel oxyimino-aminothiazolyl cephalosporin, CXA-101 (FR264205), against P. aeruginosa strains with defined resistance mechanisms as well as against multiresistant clinical CF isolates of P. aeruginosa and Burkholderia cepacia. 
Introduction
Pseudomonas aeruginosa causes significant mortality in immunosuppressed patients and is an important pulmonary pathogen in cystic fibrosis (CF) [1] .
Species belonging to the Burkholderia cepacia complex (BCC) also are important in CF, and both species are notorious for antibiotic resistance in this setting where chronic infections are exposed to repeated antimicrobial treatments [2] [3] [4] .
Resistance is more variable among nosocomial P. aeruginosa, with high rates in Eastern Europe, East Asia and South America but lower rates in the USA, UK and northwest Europe [2] [3] [4] [5] .
Ceftazidime, introduced 25 years ago, is still the most active cephalosporin against P. aeruginosa, but resistance arises due to: (i) mutational upregulation of efflux pumps, predominantly MexAB-OprM; (ii) partial or total derepression of AmpC -lactamase; and, more rarely, (iii) via acquisition of extended-spectrum -lactamases (ESBLs) or metallo--lactamases (MBLs) [4] . Resistance in CF isolates depends mostly on the accumulation of multiple mutations, with hypermutability co-selected with resistance [6] . ESBLs are rare and, where present, often belong to the PER and VEB types, not the TEM, SHV and CTX-M families predominant in Enterobacteriaceae. Carbapenems escape inactivation by AmpC and ESBLs but are compromised by loss of porin OprD and, except imipenem, by upregulated efflux as well as by MBLs [4] . Upregulated efflux and chromosomal -lactamases belonging to Classes A, B and D are reported to mediate resistance in the B. cepacia group, although their relative prevalence M a n u s c r i p t 4 and contributions are unclear and may vary among members of the complex [7] [8] [9] .
We examined the activity of CXA-101 (FR264205) [10] , a novel oxyiminoaminothiazolyl cephalosporin (Fig. 1) , against P. aeruginosa isolates and laboratory constructs with known ceftazidime and imipenem resistance mechanisms as well as against multiresistant clinical isolates of P. aeruginosa and BCC from CF patients.
Materials and methods

Test strains and isolates
The AmpC and OprD mutants as well as the P. aeruginosa PU21 transconjugants were laboratory constructs, as described previously [11] . The P.
aeruginosa strains with graded levels of 'intrinsic' resistance were clinical isolates that lacked upregulated AmpC or acquired -lactamase(s); the resistance of representatives was shown to vary in relation to efflux, and it is believed that efflux systems are the general mediators of resistance in this collection [12] .
Isolates with metallo-and VEB-1 -lactamases were recent submissions to the UK reference laboratory, as were the CF isolates of P. aeruginosa and BCC.
Since multiresistance is the usual reason for reference submission, these isolates potentially represented biased collections. 
Results
AmpC and OprD mutants
MICs of CXA-101 for fully AmpC-derepressed P. aeruginosa were 4 mg/L compared with 0.5-1 mg/L for AmpC-inducible or -deficient organisms belonging to the same isogenic series (Table 1) 
PU21 transconjugants and wild-types with metallo-and VEB -lactamases
The PU21 recipient was more susceptible to CXA-101 (MIC = 0.5 mg/L) than to ceftazidime (MIC = 2 mg/L). Most classical plasmid-mediated -lactamases did M a n u s c r i p t 6 not raise these values (Table 1) (Table 1) . MICs of CXA-101 and ceftazidime for two isolates with VEB ESBLs were >128 mg/L, whereas these organisms remained susceptible to imipenem.
Resistance to CXA-101 was reversed by clavulanic acid in these isolates, with MICs reduced to 2 mg/L (Table 1) .
Clinical isolates graded by intrinsic, efflux-mediated resistance
MICs of CXA-101 rose in parallel with those of ceftazidime for strains varying in their degree of efflux-mediated resistance to -lactams, but remained two-to A c c e p t e d M a n u s c r i p t 7 eight-fold lower than for ceftazidime (Fig. 2) , with maxima of 1-2 mg/L compared with 8-16 mg/L.
Cystic fibrosis isolates
MICs of CXA-101 for 56 CF isolates of P. aeruginosa and 53 BCC isolates are shown in Table 2 , whilst relationships between the MICs of CXA-101 and ceftazidime for these isolates are depicted in Table 3 . The isolates were mostly referred for investigation of multiresistance (see Discussion), with resistance rates of >50% except for meropenem (48%) and colistin (18%) in the case of P. aeruginosa and ceftazidime (25%) and meropenem (19%) in the case of BCC.
Fifty-seven percent of the P. aeruginosa isolates were resistant to ceftazidime at 8 mg/L, corresponding to the CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, compared with 36% with CXA-101 MICs >8 mg/L and 25% with MICs >16 mg/L; more generally, the MICs of CXA-101 for CF P. aeruginosa were two-to eight-fold lower than those of ceftazidime (Table 2 ). In the case of B. cepacia, MICs of CXA-101 were generally within one doubling dilution of those of ceftazidime, with 32% of values >8 mg/L and 19% >16 mg/L. For both species, the MICs of CXA-101 and ceftazidime were strongly inter-related (Table 3 ).
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Discussion
Against susceptible P. aeruginosa strains, CXA-101 was around two-to eight-fold more active than ceftazidime, previously accepted as the most active cephalosporin against this species. CXA-101 retained good activity, with MICs 4 mg/L against mutants totally derepressed for AmpC, supporting the earlier results of Takeda et al. [10] who related this behaviour to a 20-fold higher Michaelis constant (K m ) than ceftazidime (120 M vs. 6 M), equating to a lower affinity and a lower physiological efficiency for hydrolysis [14] . CXA-101 was also active at 2 mg/L against isolates with sufficient overexpression of efflux to raise ceftazidime MICs to 8-16 mg/L (Fig. 2) . Based on mutant results, Takeda et al. [10] suggested that CXA-101 wholly evaded the efflux pumps of P. aeruginosa. This assertion needs further investigation, both because of the present results and because Takeda et al.'s results also show no effect of these pumps on ceftazidime, which was found to be a substrate by others [15] . Nevertheless, all the data point towards CXA-101 being a weak substrate at best and this is important since upregulation of efflux and of AmpC are the most prevalent mechanisms of ceftazidime resistance in the species [4, 16] .
Resistance to CXA-101, with MICs 32 mg/L, arose for isolates and transconjugants with PER, VEB and OXA ESBLs and MBLs, all of which also conferred resistance to ceftazidime. These enzymes remain uncommon in P.
aeruginosa [4] , although PER-1 is widespread in Turkey [17] and VEB is common in East Asia and scattered elsewhere [18] . MBLs are disseminated internationally A c c e p t e d M a n u s c r i p t 9 [19] , with clonal outbreaks in widely scattered centres; nevertheless, their overall prevalence remains low. More generally, acquired -lactamases have failed to spread in P. aeruginosa as they have in Enterobacteriaceae [4] .
The CF isolates evaluated in this study represented a highly resistant group, reflecting submission bias to the reference laboratory. Among this selected collection, 57% of the P. aeruginosa isolates were non-susceptible to ceftazidime at 8 mg/L compared with 39% of UK CF isolates in a national survey in 2000 [20] and fewer than 10% of non-CF isolates in multiple surveys from 1982 to 2006 [21] . MICs of CXA-101 were broadly related to those of ceftazidime but typically were around eight-fold lower (Table 3) . Whilst the mechanisms of resistance were not examined, both our experience (Tomas et al., unpublished data) and published data [22] suggest that combinations of efflux, impermeability and derepression of AmpC are likely. CXA-101 offered less obvious gain against BCC isolates, but matched the activity of ceftazidime, which, with meropenem, is accepted as one of the most active -lactams against this group.
Taken together, these data suggest that CXA-101 has significant potential as a new antipseudomonal cephalosporin, bettering the activity of ceftazidime against M a n u s c r i p t 1   Table 1 Minimum inhibitory concentrations (MICs) for expression variants of Pseudomonas aeruginosa and for isolates with metallo--lactamase and VEB - A c c e p t e d M a n u s c r i p t M a n u s c r i p t 1 Table 2 Minimum inhibitory concentration (MIC) distributions for cystic fibrosis isolates of A c c e p t e d M a n u s c r i p t 1 
